Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 32.8% on an annualized basis producing an average annual return of 46.0%. Currently, Viking Therapeutics has a ...
Hosted on MSN
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
These players are vying for positions in the billion-dollar weight loss drug market. Demand for weight loss drugs is soaring, suggesting there's room for more than one winner. 10 stocks we like better ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results